You can buy or sell Insmed and other stocks, options, ETFs, and crypto commission-free!
Insmed, Inc. operates as a biopharmaceutical company. It focus developing and commercializing inhaled therapies for patients battling serious lung diseases that are often life threatening. Read More The firm develops and commercialization of ARIKAYCE or liposomal amikacin for inhalation for at least two identified orphan patient populations: patients with nontuberculous mycobacteria lung disease and cystic fibrosis patients with Pseudomonas aeruginosa lung infections. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
Bridgewater, New Jersey
52 Week High
52 Week Low
Stock Price, News, & Analysis for Insmed
News stories about INSM stock have been trending somewhat positive on Thursday, InfoTrie Sentiment reports. The research firm identifies negative and positive news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Insmed earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned news headlines about the biopharmaceutical company a news buzz of 1...
Seeking AlphaFeb 22
Insmed, Inc. (INSM) CEO William Lewis on Q4 2018 Results - Earnings Call Transcript
Insmed, Inc. (NASDAQ:INSM) Q4 2018 Results Earnings Conference Call February 22, 2019 8:30 AM ET Company Participants Blaine Davis - Vice President and Head of Investor Relations William Lewis - President and Chief Executive Officer Roger Adsett - Chief Commercial Officer Paolo Tombesi - Chief Financial Officer Conference Call Participants Ishmael Asante - Morgan Stanley Adam Walsh - Stifel Nicolaus Dana Flanders - Goldman Sachs Ritu Baral - Cowen and Company Joshua Schimmer - Evercore ISI Josep...
Yahoo FinanceFeb 22
Insmed: 4Q Earnings Snapshot
BRIDGEWATER, N.J. (AP) _ Insmed Inc. (INSM) on Friday reported a loss of $91.6 million in its fourth quarter. On a per-share basis, the Bridgewater, New Jersey-based company said it had a loss of $1.19. Losses, adjusted for amortization costs, were $1.17 per share. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research was for a loss of $1.11 per share. The biopharmaceutical developing inhaled treatments for patients battling rare l...
Expected May 1, Pre-Market